Publications by authors named "Pundharika Piboonsiri"
Article Synopsis
- Tuberculosis caused by Mycobacterium tuberculosis (Mtb) remains a major global health concern, and this study introduces a new method to identify large genetic insertions and deletions (indels) that have been overlooked.
- The analysis of 1,960 Mtb clinical isolates shows that harmful genetic variants are rarely found in essential survival genes, while Mtb genomes contain many partially harmful mutations.
- The research also links specific genetic variations, including indels in various genes, to patient outcomes and antibiotic resistance, offering insights that could improve tuberculosis treatment and prediction of risks.
To determine contributions of previously incarcerated persons to tuberculosis (TB) transmission in the community, we performed a healthcare facility-based cohort study of TB patients in Thailand during 2017-2020. We used whole-genome sequencing of Mycobacterium tuberculosis isolates from patients to identify genotypic clusters and assess the association between previous incarceration and TB transmission in the community. We identified 4 large genotype clusters (>10 TB patients/cluster); 28% (14/50) of the patients in those clusters were formerly incarcerated.
View Article and Find Full Text PDFThe Pilot Study of Immunogenicity and Adverse Events of a COVID-19 Vaccine Regimen: Priming with Inactivated Whole SARS-CoV-2 Vaccine (CoronaVac) and Boosting with the Adenoviral Vector (ChAdOx1 nCoV-19) Vaccine.
Vaccines (Basel)
March 2022
In response to the SARS-CoV-2 Delta variant, which partially escaped the vaccine-induced immunity provided by two doses of vaccination with CoronaVac (Sinovac), the National Vaccine Committee recommended the heterologous CoronaVac-ChAdOx1 (Oxford−AstraZeneca), a prime−boost vaccine regimen. This pilot study aimed to describe the immunogenicity and adverse events of the heterologous CoronaVac-ChAdOx1 regimen, in comparison with homologous CoronaVac, and homologous ChAdOx1. Between May and August 2021, we recruited a total of 354 participants from four vaccination groups: the CoronaVac-ChAdOx1 vaccinee (n = 155), the homologous CoronaVac vaccinee (n = 32), the homologous ChAdOx1 vaccinee (n = 47), and control group of COVID-19 patients (n = 120).
View Article and Find Full Text PDFObjective: To support the End TB strategy with an informatics system that integrates genomic data and the geographic information system (GIS) of (MTB) clinical isolates. We aim to develop a system prototype for implementing genomic data to support multiple drug-resistant tuberculosis (MDR-TB) control.
Methods: A 12-step data value chain was applied to describe the information flow within the system.